| |
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now. 
|
|
Today's Big NewsNov 30, 2022 |
| By Annalee Armstrong Two deaths have dimmed the initial glow surrounding Eisai and Biogen’s next Alzheimer’s disease therapy lecanemab. But the Japanese company now has more answers on the risks patients may need to learn to accept to receive treatment. |
|
|
|
By Nick Paul Taylor Sanofi’s oral sleeping sickness candidate acoziborole has achieved 95% efficacy in a late-phase clinical trial, delivering a boost to a global push to interrupt transmission of the parasitic disease by 2030. |
By Annalee Armstrong Janssen has picked a tau vaccine from its collaboration with neurodegenerative-focused biotech AC Immune to advance into further development. |
Sponsored by Slope Slope is revolutionizing the different levels of clinical trials through an all-in-one collaborative tool. Learn how Slope’s eClinical Supply Chain Management platform provides robust technology to the clinical trial space, covering all areas of supply management without losing sight of the chain of custody. |
|
Tuesday, December 7th, 2022 | 10am ET/7am PT In this presentation we’ll review how we established GOCHO™ cells from an adherent CHO-K1 cell line to meet current industry standards, how the choice of cloning media drove cell culture media choices for the entire cell-line development process, and more. Register now. 
|
|
By James Waldron With infectious disease and cancer vaccines in various stages of development, BioNTech has now licensed a variety of small-molecule programs from Poland’s Ryvu Therapeutics. |
Sponsored by Unlearn As leaders of clinical drug development, we owe it to trial patients to continuously innovate randomized control trial (RCT) designs that help to assuage fears of placebo by reducing the number of patients required to be enrolled in a control group — and to run faster trials that get answers sooner. |
By Annalee Armstrong Four months after laying off a chunk of its staff, X4 Pharmaceuticals has some good news to share, as the biotech’s WHIM syndrome therapy improved white blood cell counts in patients during a phase 3 trial. |
Sponsored by Ocugen Nuclear hormone receptors are master regulators of multiple molecular pathways. When used as a modifier gene therapy they could reverse the pathological phenotypes of multiple inherited retinal dystrophies (IRDs). |
By James Waldron So-called off-the-shelf cell therapies may be one of the hotter areas of biotech right now, but that doesn’t mean these companies are immune to the wave of layoffs spreading across the sector. The latest is Sana Biotechnology. |
By Nick Paul Taylor Nimbus Therapeutics is ramping up its pursuit of Bristol Myers Squibb’s plaque psoriasis drug Sotyktu, committing to moving a rival TYK2 inhibitor into phase 3 after hitting the primary endpoint in a midstage study. |
By Gabrielle Masson Enzyme engineering company Codexis has joined the crowd of biotechs culling staff and cutting programs in efforts to stay alive. |
By James Waldron Less than a month ago, Oncorus was gearing up to report on a phase 1 trial of its herpes simplex virus (HSV) drug in combination with Keytruda in solid tumors. Now, the biotech has dropped the asset, sparking layoffs and leaving the future of other candidates hanging in the balance. |
By Fraiser Kansteiner Bluebird bio has sold argenx a rare pediatric disease priority review voucher for $102 million, the companies said Wednesday. Argenx says the voucher will go toward a future marketing application for its first-in-class Fc receptor blocker efgartigimod, which snagged its initial U.S. green light as Vyvgart in generalized myasthenia gravis late last year. |
By Andrea Park Amazon Web Services unveiled a new cloud computing service this week that aims to give researchers and scientists in life sciences and healthcare a sturdier option for storing and analyzing mass amounts of individual health data. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about the rise of virtual care since the pandemic started and what its role will be moving forward. We also discuss some tactics to control rising drug prices in the U.S., like changing PBMs' business model and new companies like the one from billionaire entrepreneur Mark Cuban. |
|
|---|
|
|
|
Thursday, December 8, 2022 | 11am ET/8am PT Frontage Laboratories will dive into their Quantitative Whole Body Autoradiography (QWBA) services. They will look at Radiation Dosimetry reports that support human Absorption, Metabolism, and Excretion (hAME) studies at one of their clinical sites. Register now. 
|
|
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
